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Infection by enveloped viruses is initiated by the fusion of viral and cellular
membranes. In many cases, the viral membrane proteins that mediate
fusion must undergo conformational changes to become active. Influenza
hemagglutinin, for example, is activated by a dramatic conformational
rearrangement, triggered by the low pH of the intracellular compartment in
which fusion occurs. Structural characterization of this rearrangement has
led to a reconsideration of how hemagglutinin mediates membrane fusion.
Introduction
Enveloped viruses, all cells, and a variety of intracellular
compartments are bounded by lipid bilayers. Membrane
fusion gives viruses a means of entering cells, gametes a
means of accomplishing fertilization, and eukaryotic
cells a means of transporting, importing and exporting
proteins and other materials. In some cases, most notably
for a number of animal viruses, specific proteins that
facilitate membrane fusion have been definitively identi-
fied [1-4]. In other cases, such as sperm-egg fusion, an
excellent candidate fusion protein is available [5]. The
situation for intracellular transport and secretion is
murkier: although progress has been made in identifying
proteins with roles in targeting and/or fusion, none is
unequivocally involved in bilayer fusion [6,7].
In this review, I shall consider membrane fusion in gen-
eral and then focus on the influenza virus hemagglutinin,
which to date is the best-characterized protein with
membrane fusion activity. Although we remain far from a
molecular description of how hemagglutinin - or any
other protein - accomplishes membrane fusion, recent
results have focused our thinking in new directions.
Fusion of lipid bilayers
Fusion between apposed lipid bilayers can be divided, at
least conceptually, into two steps (Fig. 1). In the first step,
the outer membrane leaflets merge. It has been suggested
[8-10], for hemagglutinin-mediated fusion, that such
a 'hemifusion intermediate' might resemble the 'stalk'
Fig. 1. An outline of the events thought to be involved in the fusion of a closed bilayer, such as a viral particle or an intracellular vesi-
cle, and a target membrane. Fusion proteins have been omitted for clarity, although they are required for the fusion of biological mem-
branes. The process may be broken down conceptually, although not necessarily in reality, into two steps. A hemifusion intermediate
is depicted, in which only the outer leaflet lipids are able to mix. In the final product, mixing of lipids in both leaflets and also delivery
of the vesicle contents become possible.
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Fig. 2. The influenza life cycle. Influenza virions are surrounded by a lipid bilayer, which they acquire as they bud from an infected
cell. The predominant influenza membrane surface protein is hemagglutinin (red). Virus particles bind to cell surface glycoproteins or
glycolipids via the sialic acid binding sites on hemagglutinin, and are internalized by receptor-mediated endocytosis. The mild acidity
of the endosome triggers a conformational change in hemagglutinin, which renders it fusogenic. Fusion between viral and endosomal
membranes releases the viral nucleocapsid into the cell, where production of new viral particles commences.
shown in Figure 1, although the existence of such inter-
mediates and their nature has not yet been definitively
established for any protein-mediated fusion reaction. A
second step, in which the inner leaflets merge, would be
required to resolve hemifusion intermediates. The earliest
electrophysiologically detectable fusion product [11] con-
tains a small 'fusion pore' (or pores), which expands
rather gradually. Fusion proteins might have roles in any
or all steps in the process. Furthermore, they might serve
to limit potentially catastrophic side reaction, such as the
lysis of one or more of the participating membranes.
Lipid bilayers experience a strong, exponentially increas-
ing repulsion as they are brought closer than -20 A to
one another [12]. This repulsion appears to derive from
the need to remove tightly-bound water molecules from
hydrophilic lipid head groups, and is thus known as the
'hydration force'. To mediate fusion, proteins such as
hemagglutinin must therefore act to overcome or bypass
this repulsive hydration force. One way in which fusion
proteins may accomplish this is by rendering the space
between apposed bilayers more hydrophobic, thereby
promoting dehydration and facilitating close approach. A
fusion protein might expose hydrophobic surfaces in the
space between apposed membranes [13], thereby dehy-
drating this space directly. Alternatively, it might exert a
more indirect dehydrating effect by perturbing one or
both bilayers so that lipid tails in the hydrophobic bilayer
interior are exposed.
Israelachvili and coworkers [14] measured repulsion and
fusion between (protein-free) bilayers deposited on
curved mica surfaces. They found that exposing lipid tails
by partially depleting the lipids from the outer leaflets
of apposed bilayers enabled the leaflets to undergo
(hemi)fusion at reasonable forces, suggesting that the
strongly repulsive hydration force can be bypassed.
Similarly, small, highly curved vesicles, which by simple
geometrical considerations expose more of their bilayer
interior on average than larger vesicles, also fuse more
readily. These results suggest that a useful strategy for
fusion proteins might be to activate membranes for fusion
- or at least hemifusion - by perturbing or reorganiz-
ing the bilayer(s) to promote some exposure of the
hydrophobic interior [14]. If, as some models propose
(reviewed in [15]), a hemifused state is a bonafide fusion
intermediate, then a further fusion protein activity would
be required to promote the merger of the inner leaflets.
Influenza hemagglutinin
The structural and functional properties of the influenza
virus fusion protein, hemagglutinin, have been character-
ized extensively (reviewed in [1,15-20]). The influenza
virus particle is surrounded by a lipid bilayer, which it
acquires upon budding from an infected cell. The most
abundant protein in the viral membrane is hemagglu-
tinin, which plays two important roles in viral replica-
tion: it mediates binding of virus particles to cells and
fusion of the viral and cellular membranes (Fig. 2). Sialic
acids exposed at the cell surface, attached either to glyco-
proteins or glycolipids, are bound by receptor sites at the
top of the hemagglutinin molecule. Upon binding, the
virus is endocytosed. The low pH of the endosome
(-pH 5-6) triggers irreversible changes in the structure
of hemagglutinin, which subsequently promotes fusion
between viral and endosomal membranes, releasing the
viral nucleocapsid into the cell.
Hemagglutinin is a trimer of identical 70 kD subunits.
Each subunit is synthesized as a single chain, but this is
post-translationally cleaved to yield two glycopolypep-
tides, HA 1 and HA2, which remain linked by a single
disulfide bond. Each HA2 chain is anchored near its car-
boxyterminus in the viral membrane; in addition, there is
a short carboxy-terminal tail inside the membrane. Aside
from its transmembrane domain and signal sequence,
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Fig. 3. Ribbon diagrams, generated with
the program MOLSCRIPT [77], depict-
ing the structure of the bromelain-
released ectodomain of hemagglutinin(BHA) [78]. (a) BHA is shown 8 a
trimer, with the HA chains white and
the HA2 chains shaded. The bromelain
cleavage site near the carboxy terminus
of HA, and thus the viral membrane
end o the molecule, is at the base.
Overall, BHA comprises a stem domain,
consisting largely of residues from the
HA2 chains, and three more globularhead domains, composed exclusively of
HA1 residues. The sialic acid binding
sites are located in the head domains
near the membrane-distal tip of the
trimer [231. (b) A BHA monomer alone.
The chain termini are labeled, and the
fusion peptide sequence (HA2 residues1-23) is black. (Reproduced with
permission from [281.)
which is removed by signal peptidase, hemagglutinin has
one other hydrophobic region, located at the amino ter-
minus of the HA 2 chain, adjacent to the posttranslational
cleavage site. This segment, called the 'fusion peptide', is
thought to play an important role in fusion for reasons
which will be discussed below.
Detailed structural studies of hemagglutinin have been
facilitated by the observation that the protease bromelain
cleaves each HA 2 chain near the viral membrane to
release a soluble product [21] containing all but ten
residues of the ectodomain. The crystal structure of this
bromelain-released ectodomain, called BHA, was deter-
mined in 1981 (Fig. 3) [22]. The three HA 2 chains, with
some contribution from the HA 1 chains, form a stem.
The central feature of this stem is a triple-stranded, a-
helical coiled coil; each HA 2 chain contributes the top
half of its longest ox-helix to this coiled coil. The HA 1
chains form globular 'head' domains, which include the
receptor (sialic acid) binding site [23]. The fusion peptide
sequences are largely buried in the trimer interface,
about 35 A from the base of the trimer and 100 A from
the top (Fig. 3).
At a well-defined pH, BHA, like hemagglutinin, under-
goes a dramatic and irreversible conformational change,
acquiring different biochemical properties in the process
(reviewed in [1]). Low pH treatment of BHA results in
the exposure of hydrophobic moieties which mediate
binding to lipid or detergent micelles, or, in their ab-
sence, the formation of protein micelles ('rosettes') of
about eight trimers. The low-pH-treated molecules also
become accessible to a variety of proteases. In particular,
trypsin cleaves BHA rosettes at HA1 residue 27, releasing
a monomeric fragment (residues 28-328) known as
'tops'. Digestion of the remaining, still aggregated, mat-
erial with thermolysin results in the removal of HA2
residues 1-37, generating a fragment (TBHA2) that is
both soluble and trimeric.
These results strongly suggest that the fusion peptide
becomes exposed in low-pH-treated BHA and is respon-
sible for its hydrophobic properties, because removal of
the fusion peptide generates a soluble product. The
monomeric 'tops' fragment released from low-pH-
treated BHA by trypsin digestion binds sialic acid [24]
and a number of conformation-specific antibodies
[25-27] with the same affinity as BHA, indicating that
the globular head domains retain at least some elements
of their neutral-pH structure.
X-ray structural analysis of intact, low-pH-treated BHA
has not been possible, as their exposed fusion peptides
cause these molecules to aggregate. However, the crystal
structure of the soluble proteolytic fragment TBHA2 has
been determined recently [28] and sheds light on the
major conformational rearrangements that occur in the
stem region as a result of low pH treatment. Each subunit
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Fig. 4. Overview of the low-pH-induced
hemagglutinin conformational change.
The structures of BHA (a) and TBHA2(b) are aligned vertically by the single
region (blue) that is unaffected by the
conformational change. Thirty-five resi-
dues (red) are recruited to extend the
triple-stranded a-helical coiled coil
toward the amino terminus of HA; the
fusion peptide, which is proteolytically
removed in generating TBHA 2, is envis-
aged to project towards the target mem-
brane above the globular head domains.
A subdomain (green) reorients as a unit
by 180° to pack against the central
coiled coil (blue). Additional rearrange-
ment and partial disordering are seen in
membrane-proximal regions of HA2(yellow and uncolored). Regions that
have been proteolytically removed or
are apparently disordered in TBHA 2 are
left uncolored in BHA. Figure generated
using MOLSCRIPT [77].
of TBHA 2 comprises most of the HA2 chain (residues
38-175), disulfide-bonded to a small portion of the HA 1
chain (residues 1-27). A second proteolytic fragment,
comprising most of the HA1 chain (residues 28-328; the
'tops' fragment), has been crystallized as a complex with
an antibody Fab fragment; determination of the structure
of this complex is in progress (M. Knossow, personal
communication). Preliminary crystallographic analysis
supports the idea that this latter fragment resembles the
corresponding region of BHA. Thus, biochemical,
immunological, and crystallographic analyses all suggest
that if, as evidence considered below suggests, the globu-
lar head domains move during the conformational
change, they do so as rigid entities.
The HA2 chain, by contrast, undergoes an unprece-
dented degree of rearrangement at low pH, as seen by
comparing the crystal structure of TBHA2 [28] to that of
BHA (Fig. 4). Only thirty residues of each HA 2 subunit,
comprising the triple-stranded coiled coil at the center of
the stem, retain their neutral-pH conformation. Before
the TBHA 2 crystal structure was determined, it had been
suggested that rearrangements throughout the length of
the trimer are involved in the conformational change.
This suggestion was based on the observation that muta-
tions that alter the pH threshold for the conformational
change are widely distributed throughout the hemagglu-
tinin molecule [27,29,30], as are, the epitopes that are
altered or exposed by low pH treatment [25,31-33]. In
addition, electron microscopic studies of hemagglutinin
and its fragments before and after low pH exposure had
suggested that the intact molecules, as well as the isolated
stem domains, become longer and thinner as a result of
low pH treatment [34,35].
In 1993, Carr and Kim [36] proposed a detailed model
for the low-pH-induced conformational change in the
hemagglutinin stem domain. The HA 2 sequence contains
a long region of heptad repeats [36,37]; hydrophobic
residues that recur with this period often stabilize the
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Fig. 5. Comparison of TBHA 2 (right)
with the corresponding regions of BHA
(left). Only single subunits are shown for
clarity. Regions of the HA2 chain arelabeled A-H; the HA1, strand, which is
connected to HA2 via a disulfide bond,is labeled 1. Helix H is not seen in the
TBHA2 crystal structure and may be dis-
ordered in TBHA 2. (Modified from 1281.)
cores of 0a-helical coiled coils. Although this heptad
repeat region extends for 88 residues (38-125), only 34
of these (76-109) actually form a coiled coil in BHA.
The preceding residues (38-75) form a buttressing helix
and an extended loop. The following residues (110-125),
although a-helical, splay apart like the legs of a tripod.
Carr and Kim [36] proposed, therefore, that the low-pH-
induced conformational change might involve the re-
cruitment of these flanking regions into the central
coiled coil. Such a conformational change would be
made possible by the release of the fusion peptide from
its buried location, where it appears to serve as the linch-
pin that stabilizes the initial, hairpin-like stem arrange-
ment [22,29,38]. Synthetic peptides corresponding to
HA 2 residues 38-89 or 54-89 form trimers at low pH
that are virtually 100 % ax-helical [36], supporting the
suggestion that the BHA coiled coil might be extended
at least to HA 2 residue 38 as part of the conformational
change. This would result in a dramatic relocation of the
fusion peptides toward the top of the molecule.
The recently determined crystal structure of TBHA2
[28] confirms many aspects of this proposed model, and
provides a detailed explanation for other, earlier results.
The region labeled C in Figure 5 forms a coiled coil in
BHA, and retains this conformation in TBHA 2. The
buttressing helix (A) moves to the top of the molecule,
while the extended loop (B) adopts an oa-helical confor-
mation. In the TBHA 2 trimer, A, B and C form a con-
tinuous ao-helix that extends from residue 40 to 105 of
HA 2 and participates in a 100 A triple-stranded coiled
coil. It appears from the structure of this proteolytic frag-
ment that, in intact low-pH-treated BHA, the fusion
peptide must have moved by at least 100 A to one tip of
the molecule.
Further unanticipated rearrangements occur in the
remainder of the molecule. HA 2 residues 106-112 refold
from a helical conformation to form a short loop that
allows the bottom portion of the original helix (D) to
jackknife back and pack against the coiled coil. A small 3
sheet - made up of HA 2 13 strands E and F, and HA1 3
strand 1 - moves together with helix D, reorienting
about 1800. The last 13-22 residues (depending on the
subunit) are not apparent in electron density maps; they
may become disordered as a result of the conformational
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Fig. 6. Possible orientations of low-pH-
treated hemagglutinin relative to viral
and cellular membranes. The conforma-
tions of the fusion peptide (blue) and
membrane anchor segments (gray) are
hypothetical. For clarity, only one sub-
unit is shown; furthermore, most of the
HA1 chain is omitted as its disposition
relative to the HA2 chain is not known.(a) TBHA 2 is shown forming a bridge
between viral and cellular membranes.
This might represent an initial phase in
membrane fusion. (b) The fusion pep-
tide is inserted in the viral membrane,
as might occur in inactivated virus. This
orientation is supported by electron
microscopy (see text). (c) As in (b),
the fusion peptide and transmembrane
segment are inserted into the same
membrane. It seems likely that after
(or during) fusion, the hydrophobic
segments at either end of the HA2
chains must be associated with the
same membrane.
change. It cannot be ruled out, however, that the appar-
ent flexibility of HA 2 residues 154-175 is an artifact of
having cleaved HA2 at residue 175 to generate BHA,
severing the ectodomain from its transmembrane tether.
Ultimately, one would like to reconstruct the three-
dimensional structure of intact BHA, or better yet of
intact hemagglutinin itself, in its low-pH-induced con-
formation. It is possible that proteolytic cleavage leads to
further conformational rearrangements in the resulting
fragments. This possibility cannot yet be ruled out defini-
tively, although the consistency between earlier results
and the TBHA 2 structure argues that it is a substantially
faithful model for the corresponding regions of intact
hemagglutinin's low-pH-induced conformation.
Although some of the 328 residues of HAI are present in
TBHA 2 and the rest are present in the 'tops' fragment,
no clear electron density was seen for residues HAI 1-10
and 18-27 in the TBHA2 crystal structure. The apparent
disorder in this region, together with any disorder in the
region continuing from HAI 28 in 'tops', has important
consequences for modeling the location of the head
domains relative to the stem. It is possible, of course,
that this apparent flexibility is an artifact of proteolytic
fragmentation. On the other hand, it suggests that the
head domains may be attached to the stem domains by a
flexible tether, which could plausibly be 100 A long or
more. There is strong evidence that the head domains
reorient as a consequence of the conformational change
(see below); the extent to which they become flexibly
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attached, as opposed to simply adopting a new position,
remains an issue of active interest.
HA2 residues 1-37 (including the fusion peptide) are not
present in either of the soluble fragments of the low-pH-
treated protein that have been crystallized, nor are HA2
residues 176-221 (including the transmembrane domain).
These segments can be considered to be the 'active site'
of the molecule, in that they are thought to engage the
'substrate' bilayers (Fig. 6a). Both regions, particularly the
fusion peptide, have been the subject of intense interest
and will be discussed further below. HA 2 residues
154-175 are apparently disordered in at least one subunit
of TBHA 2. As the transmembrane domain begins at HA2
residue 185, HA2 residues 154-184 are potentially flexi-
ble in the intact low-pH-exposed molecule. Thus,
hemagglutinin is linked to the viral membrane by a seg-
ment of polypeptide which, if fully flexible, could extend
as far as 110 A. This hypothetical flexibility has important
implications for the possible mechanisms by which
hemagglutinin could facilitate fusion.
Connecting structure and function
In addition to its normal route of infection, influenza
virus will fuse at the appropriate pH with a variety of
target membranes, including erythrocytes and ganglio-
side-containing large unilamellar vesicles. These experi-
mentally accessible model systems have been extensively
employed in fusion studies. Membrane mixing can be
monitored with high kinetic resolution by incorporating
fluorescent probes into the viral and/or target mem-
branes [39,40]. For example, a self-quenching fluorescent
lipid analog can be incorporated into either membrane;
fusion leads to dilution of the analog and a consequent
increase in fluorescence, allowing the time-course of
fusion to be monitered.
Additional information has come from the functional
analysis of engineered hemagglutinin variants, which has
relied on mammalian expression systems. Hemagglutinin,
expressed on the surface of transfected cells, cleaved by
exogenously-added trypsin to generate HA1 and HA 2
chains and activated by low-pH treatment, mediates
fusion of cells with each other (generating multinucle-
ated syncytia) [41] or with sialylated targets such as ery-
throcytes [42]. Fusion of such hemagglutinin-expressing
cells with erythrocytes is susceptible to kinetic analysis by
labeling the erythrocyte membranes with self-quenching
fluorescent lipid analogs [43]. Mixing of the soluble
contents can also be monitored, for example by incor-
porating a soluble fluorescent probe into the interior of a
target liposome or erythrocyte [44].
Fusion with erythrocytes or with ganglioside-containing
large unilamellar vesicles is rapid at 37°C and pH 5.0,
being essentially complete within a few minutes [45,46].
Fusion does not begin immediately upon acidification,
even when virus is pre-bound to target membranes at
neutral pH. Instead, there is a lag phase during which no
fusion can be measured. This establishes that fusion is a
multistep process. Furthermore, in the absence of target
membranes, hemagglutinin becomes inactivated for
fusion upon acidification [17,46-50]. Inactivation is ex-
pected to affect the overall reaction kinetics, and needs to
be accounted for in the reaction mechanism [51,52].
The rate of fusion is dramatically reduced at 0°C, and
the lag phase, which lasts less than one second at 37 C,
is extended to about 5 minutes [46]. With the caveat that
the fusion mechanisms at 0 C and 37 °C may be differ-
ent [20], the slower kinetics at low temperature can be
exploited to study the molecular events that underlie
fusion. Exposure of the fusion peptide, and its insertion
into large unilamellar vesicles, occur early during the lag
phase at 0 C, preceding the onset of fusion [46]. This
indicates that fusion peptide exposure/insertion is not
the rate-limiting step for fusion at this temperature. The
duration of the lag phase varies non-linearly with
hemagglutinin surface density, suggesting that more than
one hemagglutinin trimer participates in the initiation of
fusion (T. Danieli andJ.M. White, personal communica-
tion). It has been suggested that several trimers must
assemble to form some type of proteinaceous support
structure for a fusion 'pore'; the dimensions of the initial
aqueous connection between the fusing partners inferred
from electrophysiogical studies are consistent with a
structure involving a small number of trimers [11,53].
Clearly, further work is required to establish the exis-
tence and detailed structure of such fusion-active
hemagglutinin assemblies.
The complete opening of the hemagglutinin head
domains appears to be a very slow process at 0 C as
judged by the exposure of buried epitopes [46]. It has
therefore been concluded that head domain opening is
not required for fusion [17,46]. It must be noted, how-
ever, that this conclusion is based on the bulk properties
of hemagglutinin in a virus-liposome mixture. It may
be that the minor population of hemagglutinin at the
fusion site, perhaps by virtue of sialic acid-head domain
interactions, behaves differently. Two lines of evidence
argue strongly that some head-domain rearrangement, if
not complete opening, is required for fusion. First,
mutations that alter the H threshold for fusion affect
residues at the interface between adjacent head domains
[27], arguing that rearrangement of this interface is
functionally significant. Second, hemagglutinin can be
rendered incapable of undergoing the conformational
change and of mediating fusion by the introduction of
engineered disulfide bonds that prevent movement of
the head domains relative to one another [54,55].
Furthermore, some head domain rearrangement would
appear necessary to allow the stem domain rearrange-
ments seen in TBHA 2 [28]. The head domain interacts
with the stem domain in BHA largely through contacts
with the extended loop B in HA 2 (Figs 4,5); this seg-
ment is helical in TBHA 2, a rearrangement that would
be predicted to 'release' the head domains.
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Most influenza strains undergo inactivation at low pH in
the absence of target membranes [17,46-49]. Inactivation
appears to correlate with gross morphological changes in
the viral coat, as visualized by electron microscopy
[34,45,49,56,57]. Influenza virions at neutral pH display
distinct, closely packed hemagglutinin spikes projecting
from the viral surface. After brief incubation at low pH,
the viral coat appears much more disorganized, with the
individual hemagglutinin trimers no longer distinguish-
able [56]. Inactivation may represent non-specific aggre-
gation of hemagglutinin trimers [48]. An alternative
explanation, however, is suggested by electron micro-
graphs of inactivated virus digested with trypsin which,
by removing HA 1 residues 28-328, allows visualization
of individual trimers [34]. Such micrographs suggest that
the trimer stems are inverted with respect to the viral
membrane (Fig. 6b), with the knobby base of TBHA 2 at
the membrane-distal tip and the fusion peptides inserted
into the viral membrane [28,34,35].
Such an inverted orientation is not inconsistent with the
X-ray structural results, which hint at a flexible connec-
tion between the membrane and the ectodomain [28]. It
is fully consistent with hydrophobic photoaffinity labeling
studies of inactivated virus, which suggest that the fusion
peptides insert into the viral membrane [58]. Finally, this
inverted orientation provides a plausible model for the
final post-fusion orientation [28] of the hemagglutinin
trimers relative to the single, fused membrane, as both
the fusion peptides and transmembrane segments are
associated with the same lipid bilayer (Fig. 6c).
The relationship between inactivation and fusion is not
yet entirely clear. It has been proposed that fusion and
inactivation, at 0 C at least, entail successive hemagglu-
tinin conformational changes [17,46]. According to this
model, full dissociation of the HA 1 head domains is not
only unnecessary for fusion activity but actually yields
inactive molecules. Others have argued, by contrast, that
the rate-limiting steps for fusion and inactivation are sim-
ilar over wide temperature and pH ranges [51]. This
seems to imply that the same conformational change can
lead to fusion or, in the absence of target membranes,
inactivation. We have suggested that the distinction
between fusion and inactivation involves the orientation
of the hemagglutinin trimer relative to the viral mem-
brane [28]. Clarifying this issue is an important goal of
further studies.
Functional dissection
The fusion peptide of hemagglutinin has received a great
deal of attention. This segment was inferred to be in-
volved in fusion by analogy with the F protein of Sendai
virus, in which a hydrophobic amino-terminal segment
is generated during proteolytic activation [59-61]. The
functional importance of the fusion peptide is supported
by the finding that it is the most highly conserved region
of hemagglutinin among influenza strains. Site-directed
mutations in the fusion peptide sequence can abolish
fusion activity without compromising hemagglutinin
biosynthesis, surface expression, post-translational cleav-
age or the low-pH-induced conformational change [62].
The inference from peptide studies and from the TBHA
structure that the fusion peptide moves more than 100 A
as a consequence of the conformational change [28,36] is
consistent with its playing a key role in fusion. After
undergoing this conformational change, the fusion pep-
tide sequence of BHA interacts with liposomes, as judged
by proteolysis experiments discussed above; this conclu-
sion has also received support from hydrophobic pho-
toaffinity labeling studies [63,64]. Studies at 0 C with
intact virus and liposomes bearing photoaffinity reagents
also suggest that, after acidification, the HA 2 chain
becomes labeled prior to the onset of fusion [65].
Presumably it is the fusion peptide that becomes labeled,
although this has not been established [66].
Attempts to explore the interaction between the fusion
peptide and membranes have made use of synthetic pep-
tide analogs of the fusion peptide. Such peptides bind
large unilamellar vesicles (and lipid monolayers) in a pH-
dependent manner [67]. Substitution of glutamate for
the glycine at position 1, which abrogates fusion in the
intact protein, diminishes the ability of the peptide ana-
log to bind membranes [67]. Peptide or-helix formation
is induced in the presence of bilayers [67-70], suggesting
that peptides may bind in a helical conformation. Such
studies are complicated, however, by the observation that
fusion peptide analogs aggregate in solution [69,70];
their aggregation state at membrane surfaces remains
uncharacterized. There is no clear consensus on the ori-
entation of bound peptide with respect to the bilayer. It
is possible that insertion of the fusion peptides destabi-
lizes the bilayer structure, as suggested by the observation
that the peptides induce leakage of large unilamellar vesi-
cles [67]. This might be accomplished efficiently by an
oblique orientation [71], as has been proposed for other
viral fusion sequences on theoretical grounds [72].
The coordinated use of site-directed mutagenesis and
synthetic peptide analogs that has begun to provide
insight into the function of the fusion peptide may prove
useful in studying other regions as well. For example,
synthetic loop peptides [36] that form o-helical trimers
at the pH of fusion may allow the design of analogs that
disfavor this structure. The same mutations, engineered
into the intact protein, could then be used to test the role
of the coiled-coil extension in fusion. It is, of course,
possible that hemagglutinin can mediate fusion via several
mechanisms, and that an alternative mechanism could
take over if the physiological one is disabled.
Recent studies by Yu et al. [73] suggest that these loop
peptides might themselves bind membranes. Peptide
analogs of HA2 54-93 (corresponding to loop B and
about half of helix C in Fig. 5) were synthesized with
cysteine substitutions for either histidine 64 or valine 84.
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Nitroxide spin labels attached to these cysteines give
characteristically sharp electron paramagnetic resonance
(EPR) spectra in aqueous solution. The peptides alone in
solution appear to be monomers at neutral pH; at low
pH, spectral line broadening is observed, presumably
reflecting interactions of the spin labels with each other.
This observation led Yu et al. to conclude that, like the
earlier loop peptides [36], these peptides might form
registered trimers.
The EPR spectra of the spin-labeled peptides at low pH
in the presence of large unilamellar vesicles are greatly
broadened, and are similar in appearance to those of
other spin-labeled peptides, such as melittin and ala-
methicin, bound to membranes. The absence of
spin-spin interactions suggests that the membrane-bound
peptides are monomeric. Based on these results, Yu et al.
proposed a model for hemagglutinin action [73] in which
the long, low-pH-induced coiled coil comes apart to
interact with the target membrane, thus drawing the tar-
get and viral membranes together. However, TBHA2
does not bind membranes [74], raising the possibility that
the membrane-binding activity seen in this study arises
from the marginal structural stability of the relatively
short peptides used [36].
The transmembrane domain of hemagglutinin may also
play an active role in fusion. A mutant hemagglutinin,
anchored by a glycosylphosphatidylinositol tail in the
outer bilayer leaflet only, mediates only a partial fusion
reaction: exchange of membrane lipids is observed, but
not mixing of the aqueous contents [75]. Although
there are other, subtle differences between the mutant
and wild-type hemagglutinins [76], it seems possible
that the replacement of the transmembrane domain,
with the consequent loss of a direct handle on the inner
leaflet, is responsible for the partial reaction observed.
This reaction may correspond to hemifusion: that is, the
fusion of the outer leaflets only (Fig. 1). It is not yet
known whether such a hemifusion intermediate lies on
the normal pathway of hemagglutinin-mediated fusion;
if so, this mutant provides an opportunity to dissect the
reaction pathway.
In summary, recent structural results have lent new
insight into the function of the membrane fusion protein
hemagglutinin. In particular, the low-pH-induced con-
formational change required for fusion appears to propel
the fusion peptide into position to interact with the tar-
get membrane. Further changes modify, and may render
more flexible, the viral-membrane-proximal portion of
the molecule. These structural conclusions derive, how-
ever, from studies of peptides and protein fragments.
While it is encouraging that they fit neatly with previous
results, it is crucial to test the hypotheses they generate
in more intact systems. Site-directed mutagenesis and
functional analysis should allow such testing to be done.
Finally, dissecting the detailed sequence of events by
which the low-pH-induced conformation facilitates
fusion must stand as a chief goal of future studies.
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